drugset / Trial / NCT06331156

A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants

NCT06331156 ↗

Phase 3 Completed 400 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the immune response and safety of the inactivated poliovirus (IPV) vaccine when co-administered with the human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in healthy Chinese infants 6-10 weeks of age at the time of study enrolment.

Timeline

Start
2024-03-22
Primary completion
2024-10-22
Completion
2024-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject HRV PCV-free Vaccine — Oral
Subject IPV Vaccine — Intramuscular

Indications